New pill could tame lung inflammation in sarcoidosis
NCT ID NCT06205121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests OATD-01, an oral drug that blocks a protein called chitinase-1, in 96 people with active pulmonary sarcoidosis. Participants take the drug or a placebo for 12 weeks to see if it reduces lung inflammation measured by PET scans. The goal is to find a new treatment option for this chronic lung condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OATD-01 (an oral drug that blocks chitinase-1, a protein involved in inflammation)
What this could lead to
If successful, this could point toward a new treatment option for people with active pulmonary sarcoidosis, potentially reducing lung inflammation without needing long-term steroids.
What could go wrong
This is an early Phase 2 trial with only 96 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- XTMAB-16 for Pulmonary Sarcoidosis Trial (NCT07680166)
- Efzofitimod for Pulmonary Sarcoidosis Trial NCT05415137
- Acthar Gel for Sarcoidosis: CXCL9 Biomarker Stud NCT02523092
- FMT for Inflammatory Diseases Trial (NCT04924270)
- Sarcoidosis Medication Adherence Study | NCT05438095
- XTMAB-16 for Pulmonary Sarcoidosis Trial (NCT05890729)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Molecure Investigative Site
WITHDRAWNBirmingham, Alabama, 35209, United States
-
Molecure Investigative Site
WITHDRAWNKansas City, Kansas, 66062, United States
-
Molecure Investigative Site
RECRUITINGBaltimore, Maryland, 21224, United States
-
Molecure Investigative Site
WITHDRAWNRochester, Minnesota, 55905, United States
-
Molecure Investigative Site
RECRUITINGCleveland, Ohio, 44195, United States
-
Molecure Investigative Site
RECRUITINGPhiladelphia, Pennsylvania, 19140, United States
-
Molecure Investigative Site
RECRUITINGCharleston, South Carolina, 29425, United States
-
Molecure Investigative Site
WITHDRAWNVejle, 7100, Denmark
-
Molecure Investigative Site
WITHDRAWNBobigny, 93000, France
-
Molecure Investigative Site
RECRUITINGMontpellier, 34295, France
-
Molecure Investigative Site
RECRUITINGParis, 75013, France
-
Molecure Investigative Site
RECRUITINGParis, 75015, France
-
Molecure Investigative Site
RECRUITINGEssen, 45239, Germany
-
Molecure Investigative Site
RECRUITINGFreiburg im Breisgau, 79106, Germany
-
Molecure Investigative Site
RECRUITINGMainz-GE, 55131, Germany
-
Molecure Investigative Site
WITHDRAWNCorfu, 49100, Greece
-
Molecure Investigative Site
RECRUITINGHeraklion, 71500, Greece
-
Molecure Investigative Site
RECRUITINGPátrai, 26500, Greece
-
Molecure Investigative Site
RECRUITINGThessaloniki, 57010, Greece
-
Molecure Investigative Site
RECRUITINGNieuwegein, 3435 CM, Netherlands
-
Molecure Investigative Site
RECRUITINGRotterdam, 3015 GD, Netherlands
-
Molecure Investigative Site
RECRUITINGBergen, 5009, Norway
-
Molecure Investigative Site
RECRUITINGOslo, 1478, Norway
-
Molecure Investigative Site
RECRUITINGBirmingham, B15 2GW, United Kingdom
-
Molecure Investigative Site
WITHDRAWNCambridge, CB2 0AY, United Kingdom
-
Molecure Investigative Site
RECRUITINGEdinburgh, EH16 4SA, United Kingdom
-
Molecure Investigative Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Molecure Investigative Site
RECRUITINGLondon, SW3 6JY, United Kingdom